Squarepoint’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Squarepoint’s Portfolio SCLN Stock Details SCLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-53,512	Closed	-$599K	–	2502
2017 Q3	$599K	Sell	53,512 -35,421	-40%	-$391K	0.01%	914
2017 Q2	$978K	Buy	88,933 +71,043	+397%	+$711K	0.02%	736
2017 Q1	$175K	Sell	17,890 -7,297	-29%	-$72.9K	﹤0.01%	1318
2016 Q4	$272K	Buy	25,187 +9,932	+65%	+$99.3K	0.01%	1212
2016 Q3	$156K	Sell	15,255 -2,800	-16%	-$30.5K	0.01%	923
2016 Q2	$236K	Buy	+18,055	New	+$237K	0.01%	833
2015 Q3	–	Sell	-11,700	Closed	-$115K	–	665
2015 Q2	$115K	Buy	+11,700	New	+$107K	0.04%	398

Squarepoint's SCLN Position: Q4 2017 in Review

Squarepoint sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 53,512 shares — an estimated $599K sold.

Squarepoint first reported a position in SCLN in Q2 2015 and held it in 7 quarters. The position peaked at $978K in Q2 2017. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.

Squarepoint reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
Squarepoint sold 53,512 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $599K.
Squarepoint first reported a position in Sciclone Pharmaceuticals Inc in Q2 2015 and held it in 7 quarters.
Squarepoint's Sciclone Pharmaceuticals Inc position peaked at $978K in Q2 2017.
0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.

Based on Squarepoint's 13F filing for Q4 2017, filed 14 Feb 2018.